IL161411A0 - Human antibodies that have mn binding and cell adhesion-neutralizing activity - Google Patents

Human antibodies that have mn binding and cell adhesion-neutralizing activity

Info

Publication number
IL161411A0
IL161411A0 IL16141102A IL16141102A IL161411A0 IL 161411 A0 IL161411 A0 IL 161411A0 IL 16141102 A IL16141102 A IL 16141102A IL 16141102 A IL16141102 A IL 16141102A IL 161411 A0 IL161411 A0 IL 161411A0
Authority
IL
Israel
Prior art keywords
binding
human antibodies
cell adhesion
neutralizing activity
neutralizing
Prior art date
Application number
IL16141102A
Other languages
English (en)
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of IL161411A0 publication Critical patent/IL161411A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL16141102A 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity IL161411A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02
PCT/US2002/033470 WO2003033674A2 (en) 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity

Publications (1)

Publication Number Publication Date
IL161411A0 true IL161411A0 (en) 2004-09-27

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16141102A IL161411A0 (en) 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity

Country Status (18)

Country Link
US (2) US7462696B2 (https=)
EP (1) EP1438339A4 (https=)
JP (2) JP2005528884A (https=)
KR (1) KR20050037478A (https=)
CN (1) CN1606569A (https=)
AR (1) AR036833A1 (https=)
BR (1) BR0213968A (https=)
CA (1) CA2463943A1 (https=)
CO (1) CO5370684A1 (https=)
DO (1) DOP2002000494A (https=)
HU (1) HUP0600335A2 (https=)
IL (1) IL161411A0 (https=)
MX (1) MXPA04003508A (https=)
PE (1) PE20030473A1 (https=)
PL (1) PL374304A1 (https=)
RU (1) RU2317998C2 (https=)
UY (1) UY27499A1 (https=)
WO (1) WO2003033674A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN106662578B (zh) * 2014-04-03 2021-11-12 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
ES2296412T3 (es) * 1998-10-23 2008-04-16 Institute Of Virology Gen y proteina mn.
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Also Published As

Publication number Publication date
US20030077277A1 (en) 2003-04-24
HUP0600335A2 (en) 2006-08-28
PE20030473A1 (es) 2003-06-26
DOP2002000494A (es) 2004-05-31
JP2010260845A (ja) 2010-11-18
CA2463943A1 (en) 2003-04-24
PL374304A1 (en) 2005-10-03
US20100240100A1 (en) 2010-09-23
UY27499A1 (es) 2003-05-30
WO2003033674A3 (en) 2003-08-21
KR20050037478A (ko) 2005-04-22
MXPA04003508A (es) 2004-07-22
RU2317998C2 (ru) 2008-02-27
CN1606569A (zh) 2005-04-13
CO5370684A1 (es) 2004-02-27
EP1438339A2 (en) 2004-07-21
RU2004115112A (ru) 2005-04-27
WO2003033674A2 (en) 2003-04-24
EP1438339A4 (en) 2008-08-27
AR036833A1 (es) 2004-10-06
BR0213968A (pt) 2005-05-10
JP2005528884A (ja) 2005-09-29
US7462696B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
HUP0600335A2 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
EP1353941A4 (en) PROT INES OF FINGER LINK OF MODIFIED GLOVE ES
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
AU2001298042A8 (en) Optimized pulsatile-flow ventricular-assist device and total artificial heart
LT2368907T (lt) Anti-abeta antikūnai ir jų panaudojimas
IL201751A (en) Compounds that bind il-17-like cytokine and antibodies
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
EP1436233A4 (en) BINDING PROTEINS WITH METALS AND RELATED METHODS
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
GB9928950D0 (en) Binding protein
IL166063A0 (en) Antibodies and uses thereof
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
GB0102717D0 (en) Cells and uses therefor
IL149506A0 (en) Human heparanase-related polypeptide and nucleic acid
IL151980A0 (en) Resistin binding proteins, their preparation and use
IL149851A0 (en) Resistin binding proteins, their preparation and use
GB0105922D0 (en) Genes and proteins, and their use
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
GB0212522D0 (en) Selective binding and analysis of macromolecules
GB0102447D0 (en) Protein variants and uses thereof
IL142187A0 (en) Resistin binding proteins, their preparation and use